Ropeginterferon alfa-2b - PharmaEssentia

Drug Profile

Ropeginterferon alfa-2b - PharmaEssentia

Alternative Names: AOP-2014; P-1101; Peg-IFN-alpha-2b; PEG-P-IFN-alpha-2b; Pegylated proline interferon-alfa-2b

Latest Information Update: 19 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PharmaEssentia Corporation
  • Developer AOP Orphan Pharmaceuticals AG; Institute of Liver and Biliary Sciences; Mayo Clinic; National Cancer Institute (USA); PharmaEssentia Corporation
  • Class Antineoplastics; Antivirals; Interferons; Polyethylene glycols; Small molecules
  • Mechanism of Action Interferon alpha 2b stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polycythaemia vera
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Polycythaemia vera
  • Phase III Essential thrombocythaemia; Hepatitis B
  • Phase II Chronic myeloid leukaemia; Hepatitis C; Myelofibrosis
  • Preclinical Cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 14 Jun 2018 Efficacy and adverse events data from a phase III trial in Polycythemia vera presented at the 23rd Congress of the European Haematology Association
  • 07 May 2018 Phase-I clinical trials in Polycythaemia vera (In volunteers) in Australia (SC) (NCT03546465)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top